Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Classic. Thanks.
Agreed. Normal trading. Great timing to be the day before Q1.. ;)
Impossible my friend. Hey while you are here, seriously.... what do you think about StemSpine and AmnioStem
Awesome. Thanks for the DD
It will most likely be after hours Ton.
Watching Doctors Said, Liu and Narayan all show excitement to now have a “fix” that spans the gap between risky drugs and all the complications of a surgery really has me excited.
This should really attract many many new doctors.
Why wouldn’t it? It’s a relatively simple procedure that has a high rate of success.
This really could spread like wildfire when it rumbles through the medical community.
We have seen patients travel far, so we know the demand is there too.
It’s been painful, but I think we are in the right spot and the right time my fellow longs!
I am jealous. Just a run back over .01 makes anything below easy pickings. Anything under .05-.10 is a deal as well.
What do you think about StemSpine and AmnioStem? Bigger than CaverStem and FemCelz or smaller. You seem to have a good understanding of the company I would appreciate your input. TIA
That will be the key to the day. Verification the toxic note is DOA
You will have to add that to your call list .... LMAO. Weeeeeeeeee
Malpractice = ambulance chaser
Like every doctor and every cop etc etc. means nothing.
Toxic notes ended yesterday. The remaining notes are normal OTC financing. The trial is not in the hands on CELZ. Waiting on the review just like all of us. Drop in PPS was due to the toxic note, which is gone. The social media videos are a great indicator of what is about to happen, not babble imo. There is no pump, the company has said very little. The doctors are into the science, not the stock, so it really is pretty cool to see tat the science is raising eyebrows.
Mr. Market will see the revs today, so that’s cool. No need for hope, you don’t see the doctors treating patients? Antonini’s 60+. You don’t see revs surpassing the burn? What about StemSpine and AmnioStem?
What’s your take on StemSpine and AmnioStem? Bigger revenue sources like I think?
My sentiments exactly. Just the motivation of the company to get back solid over .01 to maintain their QB status makes sub penny a no brainer.
Got it, would you care to offer any reasoning of how you came to that conclusion? I already provided mine.
Why is that C2?
Well said. Everyone is different with this one IMO. As noted the other day, some will flip this 80 times. They will bail out in the .007’ with the 6’s they bought this week. More power to them, just not my style. Especially with this one when they chase into the pennies.
Exactly. Folks need the before and after video clip and a few months to verify it’s all working well. It’s not like a med that your body builds up a tolerance for and the results fade away or you need more to chase the results. That is what led to this opioid crisis and now look at the issues with antibiotics. This is all natural and hitting at the perfect time.
This is a stem cell fix. Listen to what Dr Liu said in his video. You are GROWING blood vessels etc that leads to a fix of the underlying problem. You are not treating the symptoms, you’re treating the problem. HUGE difference!
Why anyone would be opposed to giving patients an alternative????
Hey CoinPadawan. Yes, I think we will be rocking this summer, but the recovery could start today. If the selling volume this past several days was the bad note clearing with help from those taking advantage of it, we should see far less selling. Not the multiple 500,000 sell blocks we have seen. We will get a good Q, maybe a great one, who knows for sure, but clearly far far better than Q1 2018 or any Q in 2018. It will solidify the direction.
My belief in the summer, which is just a few weeks away, is all the additional doctors we will see. Based only on how the tide has turned, I think we see Sanderson trained and up and running late this month. I think we see OH, TN, TX announced and trained and treating in June, along with an unknown amount that are calling and showing interest.
Like Dr Said’s, Narayan’s and Liu’s videos, this treatment fits the gap between risky drugs, and surgery. As word spreads in the medical community the doctors interested in using CaverStem and FemCelz will multiply quickly. I fully expect to see the same thing occur in Europe and likely across the Middle East and Asia for all the same reasons. Like NSX said, the Rome info was huge, very telling, backed by the Italian Ministry of Health. Imagine that backing in the USA?
When those things all align in the next several weeks everything will change here. This will go from a vastly unknown company and stock with few views on social media, to thousand and thousands of views and likes.
Adding fuel to the fire, and having the infrastructure set, CELZ will have the revs to kick in a more traditional marketing campaign and we will see the TV commercials and more IMO.
DD will tell you that the recovery time has been sufficient for the early on treated patients and the patient testimonials that we verified are being tapes will be out.
I am not sure how you can look at all of those things that are in black and white and not think buying in below .05 is a no brainer, let alone this ridiculous sub penny range.
The OTC is full of companies with less revs, worse SS that trade in the quarters. When the right folks see that here, hold on!!!!
All of this gets followed up by StemSpine then an encore with AmnioStem. I am buying all I can, locking and loaded for the foreseeable future. But, that is just me.
Nice post Gobsmacked. I agree.
Let me get this straight Lucky... you are saying CELZ doesn’t own the patents? And CELZ is not getting paid?
Do you think StemSpine will be out in late 2019 or early 2020? How much more will it add to the revenue stream?
Nice new videos from NM out today.
Anytime, but I would not expect the filing until after hours.
Nothing would surprise me with Dickerson’s background ;)
That point crossed my mind with this last note, I did not think about that regarding the Institutional investor notes. I would have to go back and look at the details, but I believe, unless time is up, that they can buy them back with the interest paid.
They may not seem shareholder friendly, but these guys are sharp and have great resumes. I am very confident that they have a plan and are executing it. We also know some offices are buying kits by the scores so rev are coming in so they could be doing any of those things now.
As we discussed, CELZ has been an on time reporting QB , less one delay, since 2016. They have a short time to get this back in the pennies and I have zero doubt the will.
I hate watching the longs frustrations and watching the bears eat honey, but I am in this for the long haul and have no worries at this point. To many patents, too many doctors signing up and inquiring not too become a big force. We also see patients calling faster and faster as they learn about the non surgical non drug fix.
This will help!
Warrant Exchange
On February 28, 2019, the Company” entered into three separate Exchange Agreements (each, an “Exchange Agreement”) with the holders (the “Warrant Holders”) of Common Stock Purchase Warrants issued by the Company in September 2018 and November 2018. Under each Exchange Agreement, the Company issued a convertible promissory note in the principal amount of $100,000 (an “Exchange Note”) to the Warrant Holder party to such Exchange Agreement in exchange for the cancellation of Common Stock Purchase Warrants held by such Warrant Holder, initially exercisable for an aggregate of 3,232,912 shares of the Company’s common stock. The exchanges were effected pursuant to Sections 3(a)(9) and 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder.
Each Exchange Note matures on February 28, 2020, bears interest at a rate of 8% per annum, and beginning 31 days after the closing date, is convertible into shares of the Company’s common stock at a conversion price equal to 65% of the Market Price of the common stock. “Market Price” as defined in each Exchange Note means the average of the two lowest “VWAPs” (as defined) of the Company’s common stock during the 15 trading days preceding the applicable conversion date.
Important for folks to read the filings and understand them fully. The audits are performed by accounting and associates who are regulated by PCOAB. The PCOAB NEVER conducts company audits. CELZ has been an on time, fully reporting QB since 2016.
Fully agree. You explained it well from the filings. Many things are coming together my friend.
Starting tomorrow it all back to a fair playing field! CELZ
For sure. Both sides know the numbers will be much better with revs showing. And the bad note DOA. Much better days ahead.
Thanks Doc.
In would disagree and say a lot has been accomplished. Like, The FDA does not regulate medical procedures performed by qualified and licensed doctors. CaverStem® has the only clinically proven procedure to treat Erectile Dysfunction with adult stem cells in the US. CaverStem® ONLY uses your own adult stem cells (not Embryonic stem cells) and they are not altered, manipulated or stored. Therefore, FDA does not object to these procedures.
CaverStem® has been shown to be effective even in patients who do not respond to PDE5 inhibitors, and, unlike PED5 inhibitors, CaverStem® and FemCelz is safe.
Several doctors in the US have been vetted and signed and are now OPEN and treating patients (Doctors Gershman, Said, Bieri, Liu, Narayan, Niemczyk and Sanderson). Currently you can make an appointment any of those locations along with Dr. Antonini in Rome, Italy.
Three shareholders are among the treated patients and can confirm the ease of the treatment for the patient. Testimonials will be published soon.
CELZ added physicians in Hawaii (Sanderson), California, Ohio, Texas and Tennessee (to be named soon) and CELZ will continually add the new physicians to the CaverStem® website as they come aboard. CELZ is adding approximately 5 doctors per month in the most recent two months.
To speed up new physician training due to the demand, CELZ added additional medical personnel to travel to each physicians office to train.
Due to the increased international demand and to compliment the existing relationship with Scott Shea, Thomas Bianchi has joined the company as the international sales representative. DD will tell you that interest in increasing in Europe.
Marketing Director David Brandt has been interviewing patients and is preparing customer testimonial videos.
CELZ has started treating the first patients with the FemCelz procedure for the treatment of female sexual dysfunction using stem cells from the patient's own bone marrow. Many of the existing CaverStem® affiliated physician's will also treat female patients for sexual function and we anticipate that they will be the leaders in progressing the FemCelz program. Doctors have been treating the first patients with FemCelz and additional doctors are scheduled to be trained in FemCelz procedures.
Over 50 domain names have been registered showing that MANY more doctors are being vetted or have shown interest. These includes MANY cities and states in the USA, and now we KNOW there are domains registered in Russia (PromoMed, Dr. Pushkar), Germany, France, Switzerland (Alto Uro, Dr. Bachmann) and Austria.
CELZ has begun a series of mailer and email campaigns introducing the CaverStem® procedure to licensed physicians in the areas of urology, OB/GYN, sexual function and plastic surgery. This campaign which will be expanded on a monthly basis with follow up mailers and emails and calls from our sales representatives. It's the goal to reach out to a minimum of 2500 new physicians each month by these methods. CELZ reported good replies from the January emails. Your DD will show you that more interest is building each month.
CELZ has also increased its online presence on Social Media and by placing banner advertising on websites and search engines attracting the active male. They are currently scripting television commercials which will be edited to direct patients to each physician in their area.
U.S. and international agreements have been reached for exclusive distribution rights for the FDA approved Generation 2 bone marrow harvest technology which has been used with multiple ED patients with excellent results, however Government exemptions are required for the ongoing import of the device in Russia. This is a slow and tedious process in getting approval, therefore CELZ progress has been delayed in Russia.
Your DD will show that Dr. Gershman has been performing the procedure with EXCELLENT results…Up to 90% success rate, even in difficult patients. CELZ has received positive feedback from treating physicians of a 70% to 90% efficacy in their patients. Obviously results differ depending on the age and health of the patient and cause and severity of their erectile dysfunction.
A one-year trial has concluded and will PROVE the same results and you can watch it here; https://clinicaltrials.gov/ct2/show/NCT03699943?recrs=deghi&fund=2&lupd_s=09%2F27%2F2018&lupd_d=14
CELZ is working on their paper for publication. This is ongoing and in compliance with contractual obligations. Once the paper has been approved by The Journal of Translational Medicine and a publication date advised, shareholders will be updated. Additionally, CELZ has designed an electronic patient registry that is intended to include data from the clinical trial, data from treating physicians using centrifuge technology with a 30cc to 60cc bone marrow aspiration and the second generation, needle only.
Revenue has now started, CELZ is cash flowing. Additional physicians are scheduled for training, patients are being treated and revenues are being generated and increasing each month. CELZ anticipates reaching financial self-sufficiency by revenues from sales in 2019.
CELZ has Institutional Investors now, slowing dilution and providing much better terms as CELZ completes the commercialization phase. The most recent notes that were issued in 2018 were renegotiated providing cash for operations.
CELZ signed with PatientGain to redesigning the website for the anticipated HUGE volume of traffic CaverStem® and FemCelz will generate. This has generated many calls to the vetted doctors.
CMTH anticipates acquiring the Virility Centers of America brand from affiliate company Creative Medical Health, Inc. The use of the Virility Centers brand is related to male and female wellness clinics, including sexual function (CaverStem® and FemCelzTM), incontinence and infertility. This brand will compliment the CaverStem® and FemCelz brands.
CaverStem® and FemCelz are just TWO of SEVERAL patents held by CMTH.
4 NEW patents were applied for in 2018.
Gershman and Ichim have already successfully commercialized Medistem.
CaverStem®, FemCelz, StemSpine & AmnioStem have all be TRADEMARKED
CaverStem is now a REGISTERED TRADEMARK. Caverstem®
And don’t forget the rest of that JD,.......
All OTCQB companies must meet the minimum bid price of $.01 per share at the close of business of at least one of the previous thirty (30) consecutive calendar days; in the event that the price falls below $.01, the company will begin a grace period of 180 calendar days to maintain a closing bid price of $.01 for ten consecutive trading days.
Agreed. It’s critical for them, and trust me they know it. I cannot explain why they are not addressing it, but I have my personal thoughts, and am not worried. They are handcuffed by the reviewers of the trial too, but like it has been mentioned, there will be patients testimonials very soon that are just as telling.
To keep it short, the ugly note is behind us after today. The other notes are all in the hands of the institutional investors and have much better terms and can be paid back etc.
Anyone would have to admit it took a while, for unknown reasons, to bring all of the doctors up to speed on the CaverStem and FemCelz needle kit training, but it is done now. You saw how happy Narayan and Liu and Antonini are.
HI, TX, TN, OH are in the hopper and going much faster now....FINALLY
Others have inquired, and my DD tells me that after the success in Italy and backing from the Ministry of Health more in Europe will be signing up this summer.
Look at the patients Antonini and NM are doing. Add in FemCelz.
All that ads up to revs ramping up quick now, FINALLY. We will get a nice peak tomorrow and see what they did in Q1.
.01 is NOT an issue, it will be several pennies when all this rolls out this summer. Watch.
That’s why longs are buying these notes as we can. We are over the hump. Watch.
All OTCQB companies must meet the minimum bid price of $.01 per share at the close of business of at least one of the previous thirty (30) consecutive calendar days; in the event that the price falls below $.01, the company will begin a grace period of 180 calendar days to maintain a closing bid price of $.01 for ten consecutive trading days.
They get a letter and have months to comply. Stand by